These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32293308)

  • 1. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
    Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L; Qian W; Cader R; Gatley K; Siddiqui H; Tabebisong E; Champion K; Kronbichler A; Lightstone L; Jayne D; Wilson E; Griffith M
    BMC Nephrol; 2024 Aug; 25(1):253. PubMed ID: 39112932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
    Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
    Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
    Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic nephrotic syndrome in Syrian children: clinicopathological spectrum, treatment, and outcomes.
    Wannous H
    Pediatr Nephrol; 2024 Aug; 39(8):2413-2422. PubMed ID: 38587559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
    Hansrivijit P; Puthenpura MM; Ghahramani N
    Clin Nephrol; 2020 Sep; 94(3):117-126. PubMed ID: 32589135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
    Xue C; Yang B; Xu J; Zhou C; Zhang L; Gao X; Dai B; Yu S; Mao Z; Mei C; Xu C
    Clin Kidney J; 2021 Apr; 14(4):1042-1054. PubMed ID: 34094516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
    Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined rituximab and plasmapheresis or plasma exchange for focal segmental glomerulosclerosis in adult kidney transplant recipients: a meta-analysis.
    Hansrivijit P; Ghahramani N
    Int Urol Nephrol; 2020 Jul; 52(7):1377-1387. PubMed ID: 32306197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
    Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).
    Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Nitta K; Tsukamoto T; Uchida S; Takeda A; Sato T; Wada T; Hayashi H; Akai Y; Fukunaga M; Tsuruya K; Masutani K; Konta T; Shoji T; Hiramatsu T; Goto S; Tamai H; Nishio S; Shirasaki A; Nagai K; Yamagata K; Hasegawa H; Yasuda H; Ichida S; Naruse T; Nishino T; Sobajima H; Tanaka S; Akahori T; Ito T; Terada Y; Katafuchi R; Fujimoto S; Okada H; Ishimura E; Kazama JJ; Hiromura K; Mimura T; Suzuki S; Saka Y; Sofue T; Suzuki Y; Shibagaki Y; Kitagawa K; Morozumi K; Fujita Y; Mizutani M; Shigematsu T; Kashihara N; Sato H; Matsuo S; Narita I; Isaka Y
    Clin Exp Nephrol; 2020 Jun; 24(6):526-540. PubMed ID: 32146646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
    Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Suzuki Y; Ohara S; Hosoya M
    Pediatr Int; 2016 Mar; 58(3):219-223. PubMed ID: 26275234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.
    Osterholt T; Todorova P; Kühne L; Ehren R; Weber LT; Grundmann F; Benzing T; Brinkkötter PT; Völker LA
    Sci Rep; 2023 Apr; 13(1):6980. PubMed ID: 37117201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal change disease and focal segmental glomerulosclerosis in adults: response to steroids and risk of renal failure.
    Moura LR; Franco MF; Kirsztajn GM
    J Bras Nefrol; 2015; 37(4):475-80. PubMed ID: 26648497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.